S. Kennedy (San Diego, United States of America)

Samumed

Author Of 3 Presentations

 Conference Calendar
Podium Presentation Osteoarthritis

13.3.4 - A 52 week Randomized, Double-Blind Phase 2 Study Of Intra-Articular, Wnt Pathway Inhibitor (SM04690) For Osteoarthritis (ID 9588)

Presentation Number
13.3.4
Topic
Osteoarthritis
Lecture Time
13:57 - 14:06
Session Name
13.3 - Clinical Trials and Outcomes (ID 781)
Corresponding Author
Authors
Disclosure
A.Gomoll, NuTech, Consultant M.Jones, Samumed, Consultant S.Kennedy, Samumed, Employee,Shareholder I. Simsek, Samumed, Employee, Shareholder C.Swearingen, Samumed, Employee,Shareholder J.Tambiah, Samumed, Employee, Shareholder
Podium Presentation Osteoarthritis

13.4.3 - Joint Space Width Criteria Can Reduce Knee OA Trial Heterogeneity: P2 Post-hoc Data From Wnt Pathway Inhibitor, SM04690 (ID 9669)

Presentation Number
13.4.3
Topic
Osteoarthritis
Lecture Time
13:39 - 13:48
Session Name
13.4 - Imaging (ID 782)
Corresponding Author
Authors
Disclosure
A.Brett, M.Bowes, iMorphics, Employee P.Conaghan, Flexion, AbbVie, Infirst, Medivir, EMDSerono, Novartis, ONO, Consultancy C.Lattermann, Samumed, Vericel, Cartiheal, Consultancy; ICRS, Board; AJSM, Cartilage, JKS, Ort J Sports Med, Reviewer S.Kennedy, C.Swearingen, J.Tambiah, Samumed, Employee
Extended Abstract (for invited Faculty only) Clinical Outcome

27.1.3 - Radiographic Outcomes were Concordant with Pain and Function Response: Post-hoc Analysis from a Phase 2 Study of SM04690, a WNT Pathway Inhibitor for Knee Osteoarthritis Treatment (ID 10586)

Presentation Number
27.1.3
Topic
Clinical Outcome
Lecture Time
12:24 - 12:36
Session Name
27.1 - Clinical Trials (ID 848)
Corresponding Author
Authors
Disclosure
C. Swearingen, Samumed, LLC, employee and shareholder S. Kennedy, Samumed, LLC, employee and shareholder J. Tambiah, Samumed, LLC, employee and shareholder